Fatal hepatic necrosis associated with parenteral gold therapy by Watkins, Paul B. et al.
Digestive Diseases and Sciences, Vol. 33, No. 8 (August 1988), pp. 1025-1029 
CASE REPORT 
Fatal Hepatic Necrosis Associated with 
Parenteral Gold Therapy 
P A U L  B. WATKINS,  MD, ROBERT SCHADE,  MD, A. SCOTT MILLS,  MD, RO BERT L. 
CARITHERS,  JR, MD, and DAVID H. VAN T H I E L ,  MD 
Parenteral  gold therapy is widely used in the long- 
term management  of  rheumatoid arthritis. Pro- 
longed cholestasis is a well-recognized toxic mani- 
festation of  this form of  therapy and is not life- 
threatening. Severe hepatocellular disease, includ- 
ing fatal hepatitis, was observed during the early 
clinical experience with chrysotherapy (1-4). How- 
ever,  with the possible exception of  a single case 
(5), this form of  liver injury has not been associated 
with gold since disposable needles and hepatitis B 
serologic testing have been in routine clinical use. It 
has therefore been suggested that these early re- 
ports represented concomitant  viral hepatitis rather 
than an idiosyncratic reaction to gold (6). 
Two patients who were receiving parenteral gold 
recently presented to our institutions with fulminant 
hepatic necrosis that could not be ascribed to hep- 
atitis A or hepatitis B. The striking similarity of  
these cases suggested the strong possibility that 
parenteral  gold contributed to the fatal liver injury. 
CASE REPORT 
Case 1. A 33-year-old black male with seronegative 
rheumatoid arthritis was admitted to a Detroit hospital on 
February 3, 1983, with a three-day history of right upper 
quadrant pain, fever, and jaundice. He noted these symp- 
toms one day after his second injection of aurothioglu- 
cose (75 mg total gold dose). His only daily medication 
was indomethacin 50 mg qid, but compliance with and the 
duration of this therapy was not documented. He denied 
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alcohol intake or exposure to hepatitis and had no history 
of blood transfusions. Serum ALT, AST, and bilirubin 
levels were normal one month earlier. 
On examination he was jaundiced and in acute distress 
because of right upper quadrant abdominal pain. Blood 
pressure was 96/48 mm Hg, pulse 110/min, and respira- 
tory rate 20/min. Temperature was 103.4 ~ F. Examination 
of the skin revealed no rashes. Liver span could not be 
assessed because of exquisite right upper quadrant ten- 
derness; splenomegaly was not evident. Neurologic ex- 
amination was within normal limits. 
Admission laboratory studies included a hemoglobin of 
7.3 g/dl; WBC 11.7 cells/mm 3 with 49 polys, 21 bands, and 
no eosinophils; platelets 315,000 cells/mm3; AST 3430 
IU/liter; ALT 2380 IU/liter; LDH 2080 IU/liter; bilirubin 
20.7 mg/dl; and alkaline phosphatase 342 IU/liter. The 
prothrombin time was prolonged by 4 sec, BUN was 21 
mg/dl, and creatinine was 1.6 mg/dl. On the second 
hospital day the patient's hemoglobin fell to 6.1 g/dl and 
melena was noted. The bilirubin level climbed to 46 mg/dl 
on the fourth hospital day. Abdominal sonography re- 
vealed no obstruction of the biliary tree. On the fourth 
hospital day ascites was noted. On the sixth hospital day 
the patient became lethargic; arterial ammonia was 150 
ixM/liter. On the seventh day urine output ceased and the 
patient developed pulmonary edema. Hemodialysis was 
begun, and the patient was flown to the University of 
Pittsburgh for possible liver transplantation 10 days after 
initial presentation. 
On admission to Presbyterian University Hospital, the 
patient required immediate intubation and positive end- 
expiratory pressure ventilation. Dialysis was continued, 
and periodic blood transfusions were given for persistent 
gastrointestinal bleeding. Laboratory studies revealed a 
white blood cell count of 18,900 cells/mm 3 with a left shift 
(2% eosinophils), platelets 20,000 cells/mm 3, alkaline 
phosphatase 24 IU/liter, ALT 10 IU/liter, total bilirubin 
32.1 mg/dl, arterial ammonia 63 txM/liters, and prothrom- 
bin time was 5 sec prolonged. Alphal-antitrypsin and 
ceruloplasmin levels were normal. Hepatitis A IgM anti- 
body was negative, and HBsAg, anti-HBc, and anti-HBs 
were absent. 
The patient underwent orthotopic liver transplantation 
on February 14, 1983, two weeks after the onset of his 
illness. The resected liver weighed 2000 g. Microscopic 
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examination revealed hepatocellular drop-out in the 
centrilobular region and portal-central bridging necrosis 
(Figure 1). On February 17, the patient was reexplored 
due to persistent intraabdominal bleeding. He did not 
regain consciousness and died soon after the second 
procedure. 
Case 2. A 23-year-old black male presented to the 
Medical College of Virginia on September 10, 1982, with 
a one-week history of progressive malaise, anorexia, and 
jaundice. He admitted to drinking one six pack of beer on 
weekends, but denied hepatitis contact or intravenous 
drug abuse and had never received a blood transfusion. 
The patient's only daily medication was ibuprofen 400 mg 
qid which he had been taking intermittently for several 
months. He had been started on weekly aurothiomalate 
injections two months before for seronegative rheumatoid 
arthritis and had received a total of 385 mg gold. 
During the examination, the patient was pleasant and 
cooperative and did not appear ill. His blood pressure 
was 130/80 mm Hg, pulse 56/min, and respiratory rate 
20/min. He was afebrile. There were no stigmata of 
chronic liver disease and no rashes, petechiae, 
echymoses, or edema. He had mild right upper quadrant 
tenderness with a liver span of 13 cm without a palpable 
edge. No spleen was felt. His mental status was normal, 
and asterixis was not present. 
Admission laboratory studies included a bilirubin of 7.7 
mg/dl, AST 3414 IU/liter, ALT 2760 IU/liter, alkaline 
phosphatase 397 IU/liter, albumin 3.4 g/dl, cholesterol 
133 mg/dl, BUN 4 mg/dl, creatinine 0.4 mg/dl, prothrom- 
bin time prolonged 6 sec, white blood cell count 5200 
cells/mm 3 with 6% eosinophils, hemoglobin 13.2 g/dl, and 
platelet count 400,000 cells/mm 3. There was no evidence 
of bile duct dilatation on ultrasonographic examination. 
Anti-HB~ was detected. HB~Ag and anti-HBr were both 
negative. 
Asterixis, lethargy, and an arterial blood ammonia level 
of 190 p.M/liter were noted on the twelfth hospital day. 
During the several subsequent days the patient's trans- 
aminase levels slowly fell, but the encephalopathy per- 
sisted and the prothrombin time continued to climb 
despite administration of exogenous clotting factors. On 
the seventeenth hospital day the patient required five 
units of blood to replace losses due to bleeding from 
stress ulcerations of the stomach. On the eighteenth 
hospital day, the patient had grand mal seizures. On the 
thirty-second hospital day, the patient's bilirubin was 20 
mg/dl, alkaline phosphatase 174 IU/liter, AST 94 IU/liter, 
ALT 40 IU/liter, albumin 2.2 g/dl, cholesterol 27 mg/dl, 
and prothrombin time 26 sec with control of 11 sec. The 
patient died on the thirty-sixth hospital day. The postmor- 
tem liver weighed 750 g and showed massive hepatic 
necrosis with focal nodules of regenerating parenchyma 
(Figure 2). 
DISCUSSION 
Jaundice has been associated with parenteral gold 
therapy since its first use in clinical medicine in the 
1920s. The incidence of jaundice reported in the 
early clinical trials of crysotherapy ranged from 
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0.25% (7) to as high as 9.4% (8). In addition, there 
were a number of early reports of fatal hepatitis in 
patients receiving gold (1--4). A single case of severe 
hepatocellular necrosis has been reported recently 
(5) in a patient who had been receiving gold injec- 
tions for longer than six months. All other recent 
reports of idiosyncratic liver reactions to gold have 
stressed the cholestatic and benign nature of the 
condition. Of these 16 cases reported since 1970 
(9-19), all patients became jaundiced within the first 
12 weeks of treatment. Total gold doses ranged 
from as low as 10 mg (13) to as high as 600 mg (15), 
and thiomalate (9-11, 13, 15, 16, 18, 19), 
thiopropanol (11), and thioglucose (14, 17) gold salt 
preparations have been implicated. Most of  the 
patients reported were only mildly symptomatic. 
Fever, rash, and eosinophilia were frequently, but 
not invariably, present. The reported biochemical 
parameters and histologic features were predomi- 
nantly those of an intrahepatic cholestasis, and 
serum transaminase levels greater than 10 times the 
upper limit of normal were reported in only one 
patient (12). Resolution of jaundice was generally 
prolonged but eventually all but a single patient (18) 
recovered. This patient, however, died of pneumo- 
nia and, at autopsy, histologic evaluation of the 
liver revealed only "mild centrizonal congestion, 
necrosis and bile stasis" (18). 
The two patients presented in this report do not 
fit the clinical pattern of gold hepatitis as recently 
reported. On admission to the hospital and prior to 
any evidence of hemodynamic instability, each pa- 
tient had serum transaminase elevations that ex- 
ceeded 70 times the upper limit of normal. In each 
patient, the liver injury proved to be fatal. 
It is not possible to establish a direct causal 
relationship between parenteral gold and the fatal 
hepatitis reported here even though each patient 
had recently begun treatment with this agent. In 
addition to gold, each patient was using a medica- 
tion which has occasionally been reported to cause 
hepatitis (20, 21). Thus, drug-induced hepatitis due 
to indomethacin and ibuprofen is possible. In addi- 
tion, in neither case could non-A, non-B viral 
hepatitis be completely excluded, as there is no 
reliable serologic marker for this condition; how- 
ever, neither patient had a history of recent dental 
work, blood transfusions, homosexuality,  or illicit 
drug use. 
Despite these reservations, the striking similarity 
of these two cases, seen at different institutions, 
and their similarity to the older reports of fatal 
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Fig 1. Case 1, liver: (A) There is complete drop-out of hepatocytes in the centrizonal region of the lobule with portal-central 
bridging necrosis. Lymphocytes are scattered throughout the lobule. C, central; P, portal (H&E, 25x). (B) Bridging necrosis 
is highlighted by reticulin collapse (Wilder's reticulin, 25x). 
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Fig 2. Case 2, liver: (A) There is panlobular necrosis with haphazardly scattered islands of viable hepatocytes. 
Pseudoductular proliferation is prominent in areas of necrosis. The field bracketed is seen at higher magnification in B 
(H&E, 25 x). (B) Clusters of viable hepatocytes are surrounded by a mixed inflammatory infiltrate composed largely 
of lymphocytes, Occasional bile plugs (arrows) are present (H&E, lOOx), 
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hepatitis following the institution of gold therapy 
raise concern that they may represent severe idio- 
syncratic reactions to gold. It has been estimated 
that seven million people suffer from rheumatoid 
arthritis in the United States alone (22). Oral gold 
preparations have recently been approved by the 
Food and Drug Administration, and it is expected 
that this will result in a great increase in the use of 
gold in this patient population (23). Awareness of 
the possibility of severe hepatocellular injury result- 
ing from the use of gold preparations alone or in 
combination with nonsteroidal antiinflammatory 
drugs may become increasingly important. 
SUMMARY 
Two young black male patients with seronegative 
rheumatoid arthritis and treated with nonsteroidal 
antiinflammatory agents developed fulminant he- 
patic necrosis following the institution of parenteral 
gold therapy. These cases, reported from different 
institutions, may represent a severe form of idio- 
syncratic gold hepatonecrosis. Awareness of the 
possible association between gold therapy and se- 
vere hepatic injury may become increasingly impor- 
tant as oral gold preparations become widely avail- 
able. 
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